Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-24-098180
Filing Date
2024-11-14
Accepted
2024-11-14 13:32:36
Documents
75
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0220960-10q_bioess.htm   iXBRL 10-Q 646189
2 CERTIFICATION ea022096001ex31-1_bioess.htm EX-31.1 21867
3 CERTIFICATION ea022096001ex32-1_bioess.htm EX-32.1 11289
4 GRAPHIC image_001.jpg GRAPHIC 7168
  Complete submission text file 0001213900-24-098180.txt   4780666

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE bioe-20240930.xsd EX-101.SCH 44953
6 XBRL CALCULATION FILE bioe-20240930_cal.xml EX-101.CAL 68802
7 XBRL DEFINITION FILE bioe-20240930_def.xml EX-101.DEF 216058
8 XBRL LABEL FILE bioe-20240930_lab.xml EX-101.LAB 415006
9 XBRL PRESENTATION FILE bioe-20240930_pre.xml EX-101.PRE 227275
78 EXTRACTED XBRL INSTANCE DOCUMENT ea0220960-10q_bioess_htm.xml XML 486228
Mailing Address 2955 MAIN STREET STE 300 IRVINE CA 92614
Business Address 2955 MAIN STREET STE 300 IRVINE CA 92614 888-816-1494
Bio Essence Corp (Filer) CIK: 0001723059 (see all company filings)

EIN.: 943349551 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-56263 | Film No.: 241459930
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)